durvalumab, gemcitabine, and cisplatin is a tolerable treatment regimen in patients with advanced biliary tract cancer👇👇👇

🔥off the press: Durvalumab + gemcitabine/cisplatin in advanced biliary tract cancer: patient-reported outcomes from TOPAZ-1
The Lancet Oncology
👉No improvement yet, but adding Durva has no detrimental effect and some long-term benefit
Author link👇
authors.elsevier.com/c/1j02A5EIIgPd…
ESMO - Eur. Oncology

🙏Many thanks PSC Support for your collaboration in the joined effort to advance these🩸biomarkers to a next level !

🏥with biological samples interested to participate are very welcome, just please contact!

👉CCA early detection is key for cure!

The final version of our recommendations to maximise the value of tissue to guide treatment when reporting intrahepatic cholangiocarcinoma have just been published AMMF Cholangiocarcinoma Foundation doi.org/10.1016/j.jhep…...

🧐Lo que debes saber sobre colangitis biliar primaria en una #infografía ➡️ journal-of-hepatology.eu/article/S0168-… vía Journal of Hepatology

#livertwitter

With the help of chiara braconi Jesus Bañales Bas Groot Koerkamp, Vincenzo Cardinale and others, we also had input from 'end-users' of pathology reports. The efforts were supported by Precision-BTC-Network EURO-CHOLANGIO-NET ENS-CCA.

Parece que después de 2 estudios contradictorios, un 3º concluye que el omeprazol (y similares) no incrementa el riesgo de encefalopatía hepática en pacientes con cirrosis

‼️ Sin embargo, destaca la sobreutilización de estos fármacos, con 3 de cada 4 pacientes sin una indicación

👏🔬Este mediodía cuatro investigadoras e investigadores de #Biogipuzkoa han recibido por parte de Contra el Cáncer en Gipuzkoa las Ayudas en Investigación 2023.

¡Muchas gracias por el apoyo y reconocimiento! 😊

🔗i.mtr.cool/owhhctadtw

📢 The last #EASLJC is now available on demand on #EASLCampus !

📺Check it now ➡️ easlcampus.eu/webinars/molec…

EASLnews #livertwitter

📢Are you ready for the next #EASLJC ?
👉Follow these steps:
1⃣ Register (FREE!): easl-eu.zoom.us/webinar/regist…
2⃣ Read the paper (see graphical abstract)
3⃣ Prepare your questions
4⃣ Join the discussion on 23 April @ 18:00 CEST
5⃣ Ask your questions in live!

EASLnews #livertwitter

Como cada año, en Contra el Cáncer en Gipuzkoa vamos a celebrar un acto en el que entregaremos las ayudas a la #investigaciónencáncer en #Gipuzkoa de este año. 🔬

➡ ¿Te gustaría asistir?
☎ Llámanos al 943 45 77 22 y confirma tu asistencia.

Biogipuzkoa

“Long-term survivors in #CCA and #BiliaryMalignancies are becoming a #reality ”, indeed.

😊

📢Don't forget to register for the next #EASLJC on Tuesday 23 April 2024 at 18:00 CET!

➡️easl-eu.zoom.us/webinar/regist…

EASLnews #livertwitter

Would love to be younger…😅

Excellent opportunity🍀👇👇